The significance of microRNA-148/152 family as a prognostic factor in multiple human malignancies: a meta-analysis
The significance of microRNA-148/152 family as a prognostic factor in multiple human malignancies: a meta-analysis
复制标题
microRNA-148/152家族作为多种人类恶性肿瘤预后因素的重要性：荟萃分析
DOI：
10.18632/oncotarget.17949
复制
发表时间：
2017-06-27
期刊：
影响因子：
--
通讯作者：
Wang, Zengjun
中科院分区：
文献类型：
--
作者：
Miao, Chenkui;Zhang, Jianzhong;Wang, Zengjun
最近的研究表明，microRNA-148/152家族成为预测肿瘤预后和进展的一个有吸引力的生物标志物。然而，不同研究的结果存在争议。通过PubMed、EMBASE和Web of Science等在线数据库检索符合条件的文献。这项荟萃分析最终纳入了24项符合条件的研究。结果显示，miR-148/152家族过表达与总生存率/病因特异性生存率（OS/CSS）显著相关（HR=0.63, 95% CI: 0.54-0.74）。分层分析表明，miR-148a和miR-148b高表达预示着良好的OS/CSS （HR=0.76; 95% CI: 0.69-0.90）和（HR=0.49; 95% CI: 0.39-0.61），而miR-152无显著影响（HR=0.40, 95% CI: 0.12-1.29）。MiR-148/152家族与亚洲人优越的OS/CSS明显相关（HR=0.53, 95% CI: 0.44-0.64），但与高加索人无关（HR=0.96, 95% CI: 0.82-1.13）。此外，miR-148/152家族表达也预测更长的疾病/复发/无进展生存期（DFS/RFS/PFS） （HR=0.37, 95% CI: 0.16-0.88）。亚洲人的DFS/RFS/PFS （HR=0.21, 95% CI: 0.06-0.81）明显优于高加索人（HR=0.76, 95% CI: 0.31-1.87）。miR-148/152家族过表达也预示着组织中DFS/RFS/PFS的延长（HR=0.11, 95% CI: 0.01-0.98），但在血浆/血清中则不然（HR=0.67, 95% CI: 0.38-1.18）。我们的荟萃分析表明，miR-148/152的过表达可以预测癌症患者的OS/CSS和DFS/RFS/PFS的提高。MiR-148a/b家族可能是多种人类恶性肿瘤的潜在预后因素。
Recent studies have demonstrated that microRNA-148/152 family emerges as a attractive biomarker for predicting tumor prognosis and progression. However, outcomes of different studies are controversial. Eligible Literature were searched through online databases: PubMed, EMBASE and Web of Science. A total of 24 eligible studies were ultimately enrolled in this meta-analysis. Results indicated that overexpression of miR-148/152 family was significantly correlated with enhanced overall/cause-specific survival (OS/CSS) (HR=0.63, 95% CI: 0.54-0.74). Stratified analysis indicated that high miR-148a and miR-148b expression predicted favorable OS/CSS (HR=0.76; 95% CI: 0.69-0.90) and (HR=0.49; 95% CI: 0.39-0.61), while miR-152 developed no significant impact (HR=0.40, 95% CI: 0.12-1.29). MiR-148/152 family was distinctly associated with superior OS/CSS in Asian (HR=0.53, 95% CI: 0.44-0.64), but not in Caucasian (HR=0.96, 95% CI: 0.82-1.13). Futhermore, miR-148/152 family expression also predicted longer disease/relapse/progression-free survival (DFS/RFS/PFS) (HR=0.37, 95% CI: 0.16-0.88). A significantly favorable DFS/RFS/PFS was observed in Asian (HR=0.21, 95% CI: 0.06-0.81) than that in Caucasian (HR=0.76, 95% CI: 0.31-1.87). miR-148/152 family overexpression also predicted longer DFS/RFS/PFS in tissues (HR=0.11, 95% CI: 0.01-0.98), but not in plasma/serum (HR=0.67, 95% CI: 0.38-1.18). Our meta-analysis demonstrated that overexpression of miR-148/152 predicted enhanced OS/CSS and DFS/RFS/PFS of cancer patients. MiR-148a/b family may serve as a potential prognostic factor in multiple human malignancies.